Core Insights - Investors in the Technology Services sector should consider Nu Holdings Ltd. (NU) and Cellebrite DI Ltd. (CLBT) for potential value opportunities [1] Valuation Metrics - Nu Holdings Ltd. has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Cellebrite DI Ltd. has a Zacks Rank of 3 (Hold) [3] - NU has a forward P/E ratio of 37.15, compared to CLBT's forward P/E of 44.66, suggesting NU is more attractively valued [5] - The PEG ratio for NU is 0.69, indicating better growth prospects relative to its valuation, while CLBT's PEG ratio is 1.95 [5] - NU's P/B ratio is 10.48, while CLBT's P/B ratio is 12.85, further supporting NU's superior valuation metrics [6] Investment Conclusion - NU has demonstrated stronger estimate revision activity and more favorable valuation metrics than CLBT, making it a more appealing option for value investors [7]

David focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term. He is a long term investor of quality stocks and uses options for strategy. David told investors to buy in March 2009 at the bottom of the financial crisis. The S&P 500 increased 367% and the Nasdaq increased 685% from 2009 through 2019. He wants to help make people money by investing in high-quality growth stocks.Analyst’s Disclosure: I/we have no stock, option or similar derivative ...

I gave a buy rating to Cellebrite (NASDAQ: CLBT ) in August as I believed the upside is no longer attractive given that valuation has risen to 31x forward EBITDA. Looking at how the share price hasI'm a passionate investor with a strong foundation in fundamental analysis and a keen eye for identifying undervalued companies with long-term growth potential. My investment approach is a blend of value investing principles and a focus on long-term growth. I believe in buying quality companies at a discount to th ...

Cellebrite DI Ltd. (NASDAQ:CLBT) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Andrew Kramer - Investor Relations Yossi Carmil - CEO Dana Gerner - CFO Thomas Hogan - Executive Chairman Conference Call Participants Shaul Eyal - TD Cowen Michael Cikos - Needham Jeffrey Van Rhee - Craig-Hallum Brian Essex - JP Morgan Jonathan Ho - William Blair Tomer Zilberman - Bank of America Max Michaels - Lake Street Capital Operator Welcome to the Cellebrite Third Quarter 2024 Financial ...

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.27%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.10, delivering a surprise of 25%.Over the last four quarters, the company ...

Leadership Transition - Cellebrite announced a planned leadership transition with CEO Yossi Carmil stepping down by December 31, 2024, and the Board initiating a search for a new CEO [1] - Thomas E. Hogan, the executive chairman, will serve as interim CEO until a new CEO is appointed [1] Company Growth and Achievements - Under Yossi Carmil's leadership since 2005, Cellebrite expanded from 18 employees to over 1,100, with a presence in more than 100 countries and approximately 7,000 customers [2] - The company transitioned to a subscription business model and launched an AI-driven Case-to-Closure platform, achieving strong, profitable growth [2] - Cellebrite's market valuation has doubled since going public in 2021, reaching approximately $4 billion [2] Future Outlook - Carmil expressed confidence in Cellebrite's strategic direction and its ability to capitalize on future opportunities, supported by a strong leadership team and a compelling strategic plan [3] - Hogan, with over 40 years of experience in technology and software, is expected to guide the company through this transition and maintain its operational execution [3]

Exhibit 99.1 Cellebrite Announces Third-Quarter 2024 Results Third-quarter 2024 revenue of $106.9 million exceeds $100 million quarterly revenue milestone for the first time in Company history Third-quarter 2024 revenue increased 27% year-over-year primarily due to 27% growth in subscription revenue ARR of $370.8 million, up 26% year-over-year Third-quarter 2024 adjusted EBITDA of $31.3 million, 29.3% adjusted EBITDA margin Company increases 2024 outlook for revenue and adjusted EBITDA, and raises the low e ...

Cellebrite DI Ltd. (CLBT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its third-quarter 2024 financial results before market open on Wednesday, November 6, 2024. Later that same morning, Cellebrite will host a live conference call and webcast to review the Company's financial results for the third quarter of 2024 and discuss its 2024 outlook. Releva ...

Have you been paying attention to shares of Cellebrite DI Ltd. (CLBT) ? Shares have been on the move with the stock up 7.7% over the past month. The stock hit a new 52-week high of $18 in the previous session. Cellebrite DI Ltd. has gained 104.2% since the start of the year compared to the 13.2% move for the Zacks Business Services sector and the 28.8% return for the Zacks Technology Services industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as i ...